Cellosaurus logo
expasy logo

Cellosaurus 5637 (CVCL_0126)

[Text version]
Cell line name 5637
Accession CVCL_0126
Resource Identification Initiative To cite this cell line use: 5637 (RRID:CVCL_0126)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
Part of: UBC-40 urothelial bladder cancer cell line index.
Doubling time: 23 hours (PubMed=26055179); ~24 hours (DSMZ=ACC-35).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: HTB9; Note=Based on the ATCC catalog number.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (ATCC=HTB-9; Cosmic-CLP=687452; DepMap=ACH-000905).
  • Mutation; HGNC; 9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (PubMed=27270441; Cosmic-CLP=687452; DepMap=ACH-000905).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; Cosmic-CLP=687452; DepMap=ACH-000905).
Genome ancestry Source: PubMed=30894373

Origin% genome
African30.56
Native American0.45
East Asian, North11.48
East Asian, South40.31
South Asian0.35
European, North4.97
European, South11.89
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_6344 (5637 subclone 1A6)CVCL_RR13 (5637rCDDP1000)CVCL_RR14 (5637rGEMCI20)
CVCL_JE91 (H/Rb-CL2)CVCL_JE92 (H/Rb-M)CVCL_D7IR (Ubigene 5637 ATRX KO)
CVCL_D7IS (Ubigene 5637 FBXW7 KO)CVCL_D7IT (Ubigene 5637 RNF43 KO)CVCL_D7IU (Ubigene 5637 RXRA KO)
CVCL_D7IV (Ubigene 5637 SPOP KO)
Sex of cell Male
Age at sampling 68Y
Category Cancer cell line
STR profile Source(s): ATCC=HTB-9; CCRID; CLS=300105; Cosmic-CLP=687452; DSMZ=ACC-35; KCLB=30009; PubMed=11416159; PubMed=17254797; PubMed=27270441; RCB=RCB1191; TKG=TKG 0605

Markers:
AmelogeninX,Y
CSF1PO11
D1S165615
D2S133825
D3S135815,17
D5S81811,12
D6S104316,20
D7S82010,11
D8S117910,16
D12S39120
D13S31711
D16S5399
D18S5116,18
D19S43313,15
D21S1136
FGA22
Penta D11
Penta E10,12
TH017,9
TPOX8,9
vWA16,18 (ATCC=HTB-9; Cosmic-CLP=687452; PubMed=27270441; TKG=TKG 0605)
18 (CCRID; CLS=300105; DSMZ=ACC-35; KCLB=30009; PubMed=11416159; PubMed=17254797; RCB=RCB1191)

Run an STR similarity search on this cell line
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=5637
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/5/cell-lines-detail-354.html
https://www.synapse.org/UC25
Publications

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=571047
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl. Cancer Inst. Monogr. 49:5-9(1978)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=7787250
Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J., Lippa M., Hatzivassiliou G., Tan J.
p53 mutations in bladder carcinoma cell lines.
Oncol. Res. 6:569-579(1994)

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11921286; DOI=10.1002/gcc.10050
Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N., Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Genes Chromosomes Cancer 34:86-96(2002)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=24459064; DOI=10.1007/s13277-013-1604-3
Pinto-Leite R., Carreira I.M., Melo J.B., Ferreira S.I., Ribeiro I.P., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.
Tumor Biol. 35:4599-4617(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3; PMCID=PMC4470036
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403.1-403.16(2015)

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002; PMCID=PMC4487788
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27270441; DOI=10.1038/onc.2016.172; PMCID=PMC5140783
Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K., Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0002001/8
ATCC; HTB-9
BCRC; 60061
BCRJ; 0026
CLS; 300105
DSMZ; ACC-35
ICLC; HTL01017
KCLB; 30009
NCBI_Iran; C450
RCB; RCB1191
RCB; RCB3676
TKG; TKG 0605
Ubigene; YC-C102
Cell line databases/resources CLO; CLO_0001421
CLO; CLO_0050845
MCCL; MCC:0000018
CLDB; cl1
CLDB; cl105
CLDB; cl7118
cancercelllines; CVCL_0126
CCRID; 1101HUM-PUMC000242
CCRID; 3101HUMTCHu01
CCRID; 3101HUMTCHu1
Cell_Model_Passport; SIDM00807
Cosmic-CLP; 687452
DepMap; ACH-000905
DSMZCellDive; ACC-35
IGRhCellID; 5637
LINCS_HMS; 50001
LINCS_LDP; LCL-1702
SKY/M-FISH/CGH; 17
Anatomy/cell type resources BTO; BTO:0003137
Biological sample resources BioSample; SAMN01821610
BioSample; SAMN03472760
BioSample; SAMN03473359
BioSample; SAMN10987658
CRISP screens repositories BioGRID_ORCS_Cell_line; 316
Chemistry resources ChEMBL-Cells; CHEMBL3308352
ChEMBL-Targets; CHEMBL612565
GDSC; 687452
PharmacoDB; 5637_20_2019
PubChem_Cell_line; CVCL_0126
Encyclopedic resources Wikidata; Q54603866
Experimental variables resources EFO; EFO_0002096
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM136228
GEO; GSM142303
GEO; GSM142309
GEO; GSM886840
GEO; GSM887903
GEO; GSM1374370
GEO; GSM1574578
GEO; GSM1669563
Polymorphism and mutation databases Cosmic; 687452
Cosmic; 715695
Cosmic; 760484
Cosmic; 845565
Cosmic; 846281
Cosmic; 928819
Cosmic; 943732
Cosmic; 1016892
Cosmic; 1046675
Cosmic; 1093983
Cosmic; 1285103
Cosmic; 1285998
Cosmic; 1927307
Cosmic; 2050427
Cosmic; 2057434
Cosmic; 2301520
Cosmic; 2444227
Cosmic; 2685930
Cosmic; 2700995
IARC_TP53; 3717
LiGeA; CCLE_867
Progenetix; CVCL_0126
Proteomic databases PRIDE; PXD003105
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number47